PI
RPRX icon

PGGM Investments’s Royalty Pharma RPRX Stock Holding History

PGGM Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-91,855
Closed -$2.42M – 365
2024
Q2 		$2.42M Buy
91,855
+2,385
+3% +$66.1K 0.03% 248
2024
Q1 		$2.72M Hold
89,470
– – 0.04% 245
2023
Q4 		$2.51M Buy
89,470
+1,986
+2% +$54.6K 0.04% 253
2023
Q3 		$2.37M Sell
87,484
-20,003
-19% -$594K 0.04% 258
2023
Q2 		$3.3M Sell
107,487
-1,638
-2% -$55.5K 0.05% 241
2023
Q1 		$3.93M Hold
109,125
– – 0.07% 231
2022
Q4 		$4.31M Buy
109,125
+3,173
+3% +$132K 0.08% 206
2022
Q3 		$4.26M Buy
+105,952
New +$4.53M 0.07% 221
2021
Q3 		– Sell
-4,135
Closed -$169K – 428
2021
Q2 		$169K Buy
+4,135
New +$176K ﹤0.01% 433

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PGGM Investments's RPRX Position: Q3 2024 in Review

PGGM Investments sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 91,855 shares — an estimated $2.42M sold.

PGGM Investments first reported a position in RPRX in Q2 2021 and held it in 9 quarters. The position peaked at $4.31M in Q4 2022. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • PGGM Investments reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • PGGM Investments sold 91,855 Royalty Pharma shares in Q3 2024, an estimated $2.42M.
  • PGGM Investments first reported a position in Royalty Pharma in Q2 2021 and held it in 9 quarters.
  • PGGM Investments's Royalty Pharma position peaked at $4.31M in Q4 2022.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on PGGM Investments's 13F filing for Q3 2024, filed 13 Nov 2024.